BMO Capital Starts Aquestive Therapeutics (AQST) at Outperform

BMO Capital analyst Gary Nachman initiates coverage on Aquestive Therapeutics (NASDAQ: AQST) with a Outperform rating and a price target of $26.00.

The analyst comments "AQST has best in-class PharmFilm drug delivery technology and a proven track record developing a robust portfolio of thin film products with improved profiles. It is evolving into a commercial company led by three late-stage CNS products, and we are particularly optimistic regarding the prospects for Libervant in refractory seizures that should become standard-of-care. There are multiple key catalysts over the next year that could take the stock meaningfully higher, as well as significant optionality from a high-value early-stage complex pipeline."

For an analyst ratings summary and ratings history on Aquestive Therapeutics click here. For more ratings news on Aquestive Therapeutics click here.

Shares of Aquestive Therapeutics closed at $16.00 yesterday.

You May Also Be Interested In

• Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
• MaxLinear (MXL) PT Raised to $105 at Stifel
• BorgWarner (BWA) PT Raised to $95 at Wolfe Research, 'Bullish Takeaways from CEO Meetings'